RARG and pancreatic neoplasm: The RARγ antagonists LY2955303 and MM11253 arrested the proliferation of the Panc-1 and PK-1 pancreatic cancer cell lines in the G1 phase of cell cycle without causing apoptosis, and the use of patient-derived organoids confirmed a tumor suppressive effect [43].